Tubize-Fin (TUB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tubize-Fin (TUB) has a cash flow conversion efficiency ratio of 0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€100.76 Million ≈ $117.80 Million USD) by net assets (€1.99 Billion ≈ $2.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TUB company net worth for the company's overall valuation and market capitalisation.
Tubize-Fin - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Tubize-Fin's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tubize-Fin Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tubize-Fin ranked by their cash flow conversion efficiency. Explore Tubize-Fin (TUB) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastroc Beverage Group Co Ltd
SHG:605499
|
0.071x |
|
Frontline Ltd
NYSE:FRO
|
0.113x |
|
Ramsay Health Care Ltd
AU:RHC
|
0.062x |
|
Banca Transilvania S.A.
RO:TLV
|
0.028x |
|
Engie Brasil Energia S.A.
SA:EGIE3
|
0.078x |
|
ENN Ecological Holdings Co Ltd
SHG:600803
|
0.023x |
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
N/A |
|
Orion Oyj B
HE:ORNBV
|
0.086x |
Annual Cash Flow Conversion Efficiency for Tubize-Fin (2004–2025)
The table below shows the annual cash flow conversion efficiency of Tubize-Fin from 2004 to 2025. View current stock price of Tubize-Fin for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.89 Billion ≈ $2.20 Billion |
€91.84 Million ≈ $107.37 Million |
0.049x | +4432.70% |
| 2024-12-31 | €1.84 Billion ≈ $2.15 Billion |
€-2.07 Million ≈ $-2.42 Million |
-0.001x | +1.28% |
| 2023-12-31 | €1.80 Billion ≈ $2.10 Billion |
€-2.05 Million ≈ $-2.39 Million |
-0.001x | -101.14% |
| 2022-12-31 | €1.75 Billion ≈ $2.05 Billion |
€174.23 Million ≈ $203.69 Million |
0.099x | +27868.38% |
| 2021-12-31 | €3.25 Billion ≈ $3.80 Billion |
€-1.16 Million ≈ $-1.36 Million |
0.000x | +52.23% |
| 2020-12-31 | €2.79 Billion ≈ $3.27 Billion |
€-2.09 Million ≈ $-2.45 Million |
-0.001x | -74.16% |
| 2019-12-31 | €2.66 Billion ≈ $3.11 Billion |
€-1.15 Million ≈ $-1.34 Million |
0.000x | -101.33% |
| 2018-12-31 | €2.34 Billion ≈ $2.74 Billion |
€75.76 Million ≈ $88.57 Million |
0.032x | -6.11% |
| 2017-12-31 | €2.12 Billion ≈ $2.47 Billion |
€72.96 Million ≈ $85.30 Million |
0.034x | -0.28% |
| 2016-12-31 | €1.96 Billion ≈ $2.29 Billion |
€67.70 Million ≈ $79.15 Million |
0.035x | +6.14% |
| 2015-12-31 | €1.95 Billion ≈ $2.28 Billion |
€63.45 Million ≈ $74.18 Million |
0.033x | +8720.77% |
| 2014-12-31 | €1.62 Billion ≈ $1.90 Billion |
€-613.00K ≈ $-716.66K |
0.000x | +28.75% |
| 2013-12-31 | €1.55 Billion ≈ $1.81 Billion |
€-823.00K ≈ $-962.17K |
-0.001x | +43.61% |
| 2012-12-31 | €1.49 Billion ≈ $1.74 Billion |
€-1.40 Million ≈ $-1.64 Million |
-0.001x | -1274.66% |
| 2011-12-31 | €1.55 Billion ≈ $1.81 Billion |
€124.00K ≈ $144.97K |
0.000x | +110.32% |
| 2010-12-31 | €1.44 Billion ≈ $1.69 Billion |
€-1.12 Million ≈ $-1.31 Million |
-0.001x | +91.77% |
| 2009-12-31 | €1.36 Billion ≈ $1.59 Billion |
€-12.79 Million ≈ $-14.96 Million |
-0.009x | -311.75% |
| 2008-12-31 | €1.20 Billion ≈ $1.40 Billion |
€5.32 Million ≈ $6.22 Million |
0.004x | +0.18% |
| 2007-12-31 | €1.26 Billion ≈ $1.47 Billion |
€5.61 Million ≈ $6.55 Million |
0.004x | -98.16% |
| 2006-12-31 | €1.36 Billion ≈ $1.58 Billion |
€327.96 Million ≈ $383.42 Million |
0.242x | +1799.40% |
| 2005-12-31 | €901.39 Million ≈ $1.05 Billion |
€-12.84 Million ≈ $-15.01 Million |
-0.014x | -376.61% |
| 2004-12-31 | €592.56 Million ≈ $692.76 Million |
€3.05 Million ≈ $3.57 Million |
0.005x | -- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.